Literature DB >> 29535107

Diagnosis of sporadic neurofibromatosis type 2 in the paediatric population.

Geetha Anand1, Grace Vasallo2, Maria Spanou2, Saumya Thomas1, Michael Pike3, Didu Sanduni Kariyawasam3, Sanjay Mehta1, Allyson Parry4, Juliette Durie-Gair5, James Nicholson6, Karine Lascelles7, Vanessa Everett7, Frances Mary Gibbon8, Nicola Jarvis9, John Elston10, Dafydd Gareth Evans9, Dorothy Halliday11.   

Abstract

OBJECTIVE: Onset of symptoms in severe sporadic neurofibromatosis type 2 (NF2) is typically within childhood; however, there is poor awareness of presenting features in young children, potentially resulting in delayed diagnosis and poorer outcome. We have reviewed presentation of sporadic paediatric NF2 to raise awareness of early features, highlighting those requiring further investigation.
DESIGN: Patients diagnosed with NF2 at age ≤16 and seen between 2012 and 2015 were notified via the British Paediatric Neurology Surveillance Unit or identified through the English NF2 service.
RESULTS: Epidemiological data estimate that 1 in 110 611 births are affected with childhood-onset NF2. Notes of 32 patients with sporadic NF2 were reviewed. Of those presenting under the age of 5, 89% (17/19) had ocular, 74% (14/19) dermatological and 58% (11/19) neurological signs; in 84% (16/19) features were multisystemic. Sixty-six per cent (21/32) had ≥1 atypical feature, including cerebellar hypoplasia in three cases (9%) and focal cortical dysplasia in five out of seven seizure-related presentations. Five cases presented with a sometimes transient or intermittent cranial nerve mononeuropathy. The mean delay to diagnosis was 3.16 years; in eight cases (25%) this exceeded 6 years. Most significant delay occurred in mononeuropathy, ophthalmological and/or seizure presentations, with a mean delay of 3, 4.5 and 6 years, respectively. Eighty-four per cent (27/32) of cases needed intervention in childhood.
CONCLUSIONS: All non-vestibular schwannoma NF2 presentations in childhood had significant diagnostic delay. We emphasise the importance of detailed assessment of skin and eyes in unusual presentations and propose an aide to prompt timely referral to specialist services. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  Nf2; neurofibromatosis type 2; paediatrics; sporadic

Mesh:

Year:  2018        PMID: 29535107     DOI: 10.1136/archdischild-2017-313154

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  5 in total

1.  Main Symptom that Led to Medical Evaluation and Diagnosis of Vestibular Schwannoma and Patient-Reported Tumor Size: Cross-sectional Study in 1,304 Patients.

Authors:  Maria Peris-Celda; Christopher S Graffeo; Avital Perry; Panagiotis Kerezoudis; Nicole M Tombers; Matthew L Carlson; Michael J Link
Journal:  J Neurol Surg B Skull Base       Date:  2018-10-09

2.  Introduction to phacomatoses (neurocutaneous disorders) in childhood.

Authors:  Martino Ruggieri; Agata Polizzi; Gioacchino Paolo Marceca; Stefano Catanzaro; Andrea D Praticò; Concezio Di Rocco
Journal:  Childs Nerv Syst       Date:  2020-09-17       Impact factor: 1.475

3.  Dermatologic manifestations in paediatric neurofibromatosis type 2: a cross sectional descriptive multicentric study.

Authors:  S Legoupil; D Bessis; F Picard; S Mallet; J Mazereeuw; A Phan; D Dupin-Deguine; M Kalamarides; C Chiaverini
Journal:  Orphanet J Rare Dis       Date:  2022-06-21       Impact factor: 4.303

4.  Brainstem ischemic syndrome in juvenile NF2.

Authors:  John W Henson; Tara Benkers; Connor McCormick
Journal:  Neurol Genet       Date:  2020-06-16

Review 5.  Genomics, Epigenetics, and Hearing Loss in Neurofibromatosis Type 2.

Authors:  Christine T Dinh; Eric Nisenbaum; Darius Chyou; Carly Misztal; Denise Yan; Rahul Mittal; Juan Young; Mustafa Tekin; Fred Telischi; Cristina Fernandez-Valle; Xue-Zhong Liu
Journal:  Otol Neurotol       Date:  2020-06       Impact factor: 2.619

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.